← Back to headlines
Aurinia Pharmaceuticals Eyes Growth Following LUPKYNIS Patent Settlement with Teva
Analysts evaluate whether Aurinia Pharmaceuticals' recent patent settlement for its kidney disease drug LUPKYNIS with Teva could drive significant stock gains for investors.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Rabies Detected in Baby Goats at North Carolina Mobile Petting Zoo
5h ago
48-Year-Old Anesthesiologist Found Dead in Greek Hospital On-Call Room
23h ago
Art World Mourns Yayoi Kusama as Tributes Highlight Her Lasting Creative Legacy
23h ago
Study Reveals Hidden Arterial Calcification in Young Adults
1d ago